Shares Outstanding History
Cash Position
Cash Position
The company has -82.0 months of cash left based on the quarterly cash burn of $-1.42 B and estimated current cash of $-38.84 B.
Commentary on Financial Condition
“Information related to the company's liquidity and capital resources can be found in the company’s 2025 Annual Report, Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations, Liquidity & Capital Resources. The discussion below provides the updates to this information for the six months ended June 30, 2026. The increase in debt balances from December 31, 2025 was primarily due to higher short-term debt, which was used to fund the company's working capital needs, including the Bayer resolution payment and the FMC rimisoxafen prepayment, as well as capital spending, dividend payments and share repurchases. See further information in Note 11 - Short-Term Borrowings, Long-Term Debt and Available Credit Facilities, to the interim Consolidated Financial Statements.” (from July 2026 filing’s Liquidity and Capital Resources) Filed At: 2026-07-31
| 10-Q | Form 10-Q | 2026-08-01 |
| 10-Q | Form 10-Q | 2026-05-07 |
| 10-K | Form 10-K | 2026-02-13 |
| 10-Q | Form 10-Q | 2025-11-06 |
| 10-Q | Form 10-Q | 2025-08-08 |
| 8-K | Form 8-K | 2025-05-15 |
| 424B2 | Form 424B2 | 2025-05-14 |
| FWP | Form FWP | 2025-05-13 |